Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity.

Autor: Griffin GK; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Wu J; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Iracheta-Vellve A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Patti JC; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hsu J; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Davis T; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dele-Oni D; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Du PP; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Halawi AG; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Ishizuka JJ; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Internal Medicine (Oncology), Yale Cancer Center and Yale School of Medicine, New Haven, CT, USA., Kim SY; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Klaeger S; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Knudsen NH; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Miller BC; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Immunology and Evergrande Center for Immunological Diseases, Harvard Medical School, Boston, MA, USA., Nguyen TH; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Olander KE; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Papanastasiou M; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Rachimi S; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Robitschek EJ; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Schneider EM; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Yeary MD; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Zimmer MD; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Jaffe JD; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Inzen Therapeutics, Cambridge, MA, USA., Carr SA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Doench JG; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Haining WN; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Merck, Boston, MA, USA., Yates KB; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA., Manguso RT; Broad Institute of MIT and Harvard, Cambridge, MA, USA. rmanguso@mgh.harvard.edu.; Department of Medicine and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. rmanguso@mgh.harvard.edu., Bernstein BE; Broad Institute of MIT and Harvard, Cambridge, MA, USA. bernstein.bradley@mgh.harvard.edu.; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. bernstein.bradley@mgh.harvard.edu.

Publikováno v: Nature [Nature] 2021 Jul; Vol. 595 (7866), pp. 309-314. Date of Electronic Publication: 2021 May 05.